A day after rumors swirled that Johnson & Johnson wants to tell its Cerenovus stroke care business, the company launched its latest CEREGLIDE™ 92 catheter system for acute ischemic stroke. The new next-generation device is aimed at facilitating the insertion and guidance of interventional tools within the brain’s blood vessels.
CEREGLIDE catheters are thin, flexible tubes inserted into blood vessels to assist in various medical interventions. Most notably, they allow access to the M1 segment of the brain’s middle cerebral artery, a common site for blockages that cause strokes. With this device, medical personnel can remove blood clots via mechanical thrombectomy but also treat aneurysms and other neurovascular complications by providing a larger inner lumen.
The next-gen 092-inch catheter system is engineered to facilitate the insertion and guidance of neurovascular devices while providing large distal access and improved procedural control. Using CEREGLIDE™ 92, physicians aspiration catheters during thrombectomy procedures. The method involves either direct clot removal or a combination of aspiration and stent retriever technology.
However, the biggest advancement in the new model is that it addresses the anatomical challenges of these devices. Notably, “INNERGLIDE™ 9 Delivery Aid” enhances navigation through the brain’s intricate vascular network, while “BRITE-LINE™ Technology” enhances precision by ensuring full catheter visibility under fluoroscopy. Finally, the TruCourse™ Technology flexible tip allows operators to improve trackability through narrow blood vessels.
“Vessel tortuosity and complex anatomy can make thrombectomy procedures difficult. The CEREGLIDE™ 92 catheter provides seamless access to the M1, reduces procedure time, and enhances patient outcomes,” said Dr. Brian Jankowitz, Chief of Neurosurgery at Hackensack Meridian Neuroscience Institute.
Johnson & Johnson MedTech also made efforts toward sustainability by integrating electronic instructions for use (e-IFUs) to reduce paper waste and carbon emissions.
“With CEREGLIDE™ 92, we are not only improving procedural efficiency but also expanding access to next-generation stroke technology to benefit more patients,” highlighted Mark Dickinson, Worldwide President of Johnson & Johnson Neurovascular.
Article and image source by Johnson & Johnson MedTech
